141 related articles for article (PubMed ID: 17401296)
1. HDL function as a target of lipid-modifying therapy.
Watson KE; Ansell BJ; Watson AD; Fonarow GC
Rev Cardiovasc Med; 2007; 8(1):1-8. PubMed ID: 17401296
[TBL] [Abstract][Full Text] [Related]
2. High-density lipoprotein function recent advances.
Ansell BJ; Watson KE; Fogelman AM; Navab M; Fonarow GC
J Am Coll Cardiol; 2005 Nov; 46(10):1792-8. PubMed ID: 16286161
[TBL] [Abstract][Full Text] [Related]
3. Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention.
Parhofer KG
Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):414-7. PubMed ID: 16151973
[TBL] [Abstract][Full Text] [Related]
4. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.
Kontush A; Chapman MJ
Pharmacol Rev; 2006 Sep; 58(3):342-74. PubMed ID: 16968945
[TBL] [Abstract][Full Text] [Related]
5. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
[TBL] [Abstract][Full Text] [Related]
6. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
[TBL] [Abstract][Full Text] [Related]
7. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
8. Nicotinic acid and other therapies for raising high-density lipoprotein.
Carlson LA
Curr Opin Cardiol; 2006 Jul; 21(4):336-44. PubMed ID: 16755203
[TBL] [Abstract][Full Text] [Related]
9. The paradox of dysfunctional high-density lipoprotein.
Ansell BJ; Fonarow GC; Fogelman AM
Curr Opin Lipidol; 2007 Aug; 18(4):427-34. PubMed ID: 17620860
[TBL] [Abstract][Full Text] [Related]
10. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
Thoenes M; Oguchi A; Nagamia S; Vaccari CS; Hammoud R; Umpierrez GE; Khan BV
Int J Clin Pract; 2007 Nov; 61(11):1942-8. PubMed ID: 17935553
[TBL] [Abstract][Full Text] [Related]
11. Targeting the anti-inflammatory effects of high-density lipoprotein.
Ansell BJ
Am J Cardiol; 2007 Dec; 100(11 A):n3-9. PubMed ID: 18047850
[TBL] [Abstract][Full Text] [Related]
12. The double jeopardy of HDL.
Navab M; Ananthramaiah GM; Reddy ST; Van Lenten BJ; Ansell BJ; Hama S; Hough G; Bachini E; Grijalva VR; Wagner AC; Shaposhnik Z; Fogelman AM
Ann Med; 2005; 37(3):173-8. PubMed ID: 16019715
[TBL] [Abstract][Full Text] [Related]
13. [High density lipoproteins (HDL). A therapeutic objective in the atherosclerosis prevention?].
Pérez-Méndez O
Arch Cardiol Mex; 2004; 74(1):53-67. PubMed ID: 15125268
[TBL] [Abstract][Full Text] [Related]
14. Atherosclerosis regression and high-density lipoproteins.
Lee JM; Choudhury RP
Expert Rev Cardiovasc Ther; 2010 Sep; 8(9):1325-34. PubMed ID: 20828355
[TBL] [Abstract][Full Text] [Related]
15. High-density lipoproteins, inflammation and oxidative stress.
Tabet F; Rye KA
Clin Sci (Lond); 2009 Jan; 116(2):87-98. PubMed ID: 19076062
[TBL] [Abstract][Full Text] [Related]
16. [Fibrates and markers of inflammation].
Broncel M
Pol Merkur Lekarski; 2007 Jan; 22(127):58-61. PubMed ID: 17477093
[TBL] [Abstract][Full Text] [Related]
17. Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence.
Nofer JR; Walter M; Assmann G
Expert Rev Cardiovasc Ther; 2005 Nov; 3(6):1071-86. PubMed ID: 16292998
[TBL] [Abstract][Full Text] [Related]
18. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
Staels B; Maes M; Zambon A
Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic management of isolated low high-density lipoprotein syndrome.
Bermúdez V; Cano R; Cano C; Bermúdez F; Arraiz N; Acosta L; Finol F; Pabón MR; Amell A; Reyna N; Hidalgo J; Kendall P; Manuel V; Hernández R
Am J Ther; 2008; 15(4):377-88. PubMed ID: 18645343
[TBL] [Abstract][Full Text] [Related]
20. Dyslipidaemia in diabetic patients: time for a rethink.
Shepherd J
Diabetes Obes Metab; 2007 Sep; 9(5):609-16. PubMed ID: 17697054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
